Mobius bands together $3.5M for glaucoma
Mobius Therapeutics, a St. Louis developer of glaucoma treatments, raised $3.5 million in a first funding round, VentureWire reports (subscription required). Individual investors provided the cash.
From the VentureWire story:
Based in St. Louis, [President Ed] Timm founded Mobius last April with a novel device and a reformulation of an already approved drug, trabomycin, which he said has been used off-label for glaucoma surgery for several years. “What we’ve attempted to do is take an uncontrolled exercise and give it some uniformity,” he said.
Timm said he hopes to seek 505(b)(2) approval in August from the Food and Drug Administration, which would allow him to bypass clinical trials even though the product is being classed as a drug.
Next Story: Associated Content's bold media strategy — relying on Google
Previous Story: Solar company SolFocus buys Inspira, a solar tracker company
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
